IMA203 vs standard treatment for advanced skin cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called cutaneous melanoma that has spread or cannot be removed.
- You must have a specific cell marker called HLA-A*02:01 (determined by a blood test).
- Your cancer must have gotten worse after at least one treatment with a PD-1 inhibitor (like Keytruda or Opdivo).
- If you have a BRAF gene mutation, you must have already tried a BRAF-targeted treatment (with or without a MEK inhibitor).
- You must be well enough to be up and about (ECOG score 0 or 1) and have a life expectancy of more than 6 months.
- You must have recovered from side effects of prior treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
This trial tests a combination of two medicines: one that trains your immune cells to find cancer (ACTengine IMA203) and another that helps the body recognize the tumor (mRNA-4203). It's for people with advanced melanoma or synovial sarcoma who have already tried other treatments.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Melanoma, Cutaneous Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.